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Reactive astrocytes in Amyotrophic Lateral Sclerosis (ALS) change their molecular
expression pattern and release toxic factors that contribute to neurodegeneration and
microglial activation. We and others identified a dysregulated inflammatory miRNA
profile in ALS patients and in mice models suggesting that they represent potential
targets for therapeutic intervention. Such cellular miRNAs are known to be released
into the secretome and to be carried by small extracellular vesicles (sEVs), which
may be harmful to recipient cells. Thus, ALS astrocyte secretome may disrupt cell
homeostasis and impact on ALS pathogenesis. Previously, we identified a specific
aberrant signature in the cortical brain of symptomatic SOD1-G93A (mSOD1) mice,
as well as in astrocytes isolated from the same region of 7-day-old mSOD1 mice, with
upregulated S100B/HMGB1/Cx43/vimentin and downregulated GFAP. The presence
of downregulated miR-146a on both cases suggests that it can be a promising
target for modulation in ALS. Here, we upregulated miR-146a with pre-miR-146a, and
tested glycoursodeoxycholic acid (GUDCA) and dipeptidyl vinyl sulfone (VS) for their
immunoregulatory properties. VS was more effective in restoring astrocytic miR-146a,
GFAP, S100B, HMGB1, Cx43, and vimentin levels than GUDCA, which only recovered
Cx43 and vimentin mRNA. The miR-146a inhibitor generated typical ALS aberrancies
in wild type astrocytes that were abolished by VS. Similarly, pre-miR-146a transfection
into the mSOD1 astrocytes abrogated aberrant markers and intracellular Ca2+ overload.
Such treatment counteracted miR-146a depletion in sEVs and led to secretome-
mediated miR-146a enhancement in NSC-34-motor neurons (MNs) and N9-microglia.
Secretome from mSOD1 astrocytes increased early/late apoptosis and FGFR3 mRNA in
MNs and microglia, but not when derived from pre-miR-146a or VS-treated cells. These
last strategies prevented the impairment of axonal transport and synaptic dynamics
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by the pathological secretome, while also averted microglia activation through either
secretome, or their isolated sEVs. Proteomic analysis of the target cells indicated that
pre-miR-146a regulates mitochondria and inflammation via paracrine signaling. We
demonstrate that replenishment of miR-146a in mSOD1 cortical astrocytes with pre-
miR-146a or by VS abrogates their phenotypic aberrancies and paracrine deleterious
consequences to MNs and microglia. These results propose miR-146a as a new causal
and emerging therapeutic target for astrocyte pathogenic processes in ALS.
Keywords: amyotrophic lateral sclerosis, astrocyte-microglia communication, astrocyte-motor neuron crosstalk,
calcium signaling aberrancies, glycoursodeoxycholic acid, reactive astrocytes, small extracellular vesicles,
vinyl sulfone
INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative
disease with a life expectancy of only 3 years. It is unclear where
the disease originates, or which are the specific targets, mediators,
and the underlying ALS mechanisms involved, hindering the
search for an effective therapeutic strategy. Though the majority
of cases occurs in people with no prior family history, several
mutations in different genes were already identified (Mejzini
et al., 2019), and the mutant Cu/Zn superoxide dismutase 1
(mSOD1) mouse is the mostly widely used animal model in
research. This model is well characterized in terms of behavior,
histopathology, and molecular mechanisms, and recapitulates
most of the pathological features of the human ALS (Al-Chalabi
et al., 2017). Although motor neuron (MN) loss is believed to
be the predominant feature, astrogliosis has a key role in MN
degeneration due to the release of unknown toxic factors, either
in the brain cortex or in the spinal cord (SC) (Robberecht and
Philips, 2013; Gomes et al., 2020), and in both sporadic ALS
(sALS) (Varga et al., 2018) and familiar ALS (fALS) (Meyer et al.,
2014; van Rheenen et al., 2016).
Astrocytes isolated from the SC of symptomatic rats exhibit
low levels of glial fibrillary acidic protein (GFAP) and glutamate
transporter 1 (GLT-1), together with increased S100B and Cx43,
and were designated as aberrant astrocytes (Díaz-Amarilla et al.,
2011). We lately confirmed this same set of aberrant/reactive
markers in astrocytes isolated from the SOD1G93A (mSOD1)
mice at 7-day-old and cultured for 13 days in vitro (DIV) (Gomes
et al., 2019; Gomes et al., 2020), pointing that such astrocytes
acquire early deficits associated to a disease-specific phenotype,
including low levels of GFAP. These low levels of GFAP were also
found in other harmful conditions (Escartin et al., 2021).
The secretome from ALS aberrant astrocytes was shown to
potentiate MN death (Díaz-Amarilla et al., 2011; Trias et al.,
2017; Gomes et al., 2019), and to lead to activated microglia
(Filipi et al., 2020), but the underlying neurotoxic processes
and how the factors involved are disseminated are still to be
clarified. One of the mechanisms may relate with the secretion
of small extracellular vesicles (sEVs) from mSOD1 astrocytes
with miRNAs (Jovicic and Gitler, 2017) and mSOD1 protein
(Basso et al., 2013) that showed to cause the selective death of
MNs. We previously found that the aberrant mSOD1 cortical
astrocytes expressed reduced levels of miR-146a (Gomes et al.,
2019). We also identified reduced levels of miR-146a in sEVs
released from both cortical and spinal 13 DIV astrocytes
that when cocultured with MNs showed to determine several
dysfunctionalities (Gomes et al., 2020). We then wonder whether
such depleted levels of miR-146a in mSOD1 astrocytes and
their sEVs could relate with the cell pathological features and
have harmful consequences to nearby MNs and microglia. In
conformity, recent data with astrocytes directly converted from
the C9orf72 patient fibroblasts has shown that their released
sEVs with downregulated miR-494-3p caused neuronal network
degeneration (Varcianna et al., 2019).
miRNAs are a class of small non-coding RNAs that play
important roles in regulating gene expression. Among them some
are more closely associated with inflammatory pathways, i.e.,
miR-155, miR-146a, miR-21 and miR-124, and are designed as
inflamma-miRNAs (Brites, 2020). Their dysregulation was found
in ALS (Butovsky et al., 2012; De Felice et al., 2014; Freischmidt
et al., 2014), and they were suggested to be potential biomarkers
(Ricci et al., 2018; Joilin et al., 2019). Upregulation of miR-
155 was found in fALS and sALS patients (Koval et al., 2013;
Butovsky et al., 2015), as well as in the SC of mSOD1 mice,
in either pre-symptomatic or symptomatic stages (Cunha et al.,
2018). When targeted in microglia, its reduction counteracted
microglia activation and attenuated the disease in the mSOD1
mice (Butovsky et al., 2015). Our discovered depletion of miR-
146a in aberrant cortical astrocytes and their sEVs may also
determine a polarized pro-inflammatory microglia phenotype if
we consider that it has a key role in repressing inflammation
(Taganov et al., 2006; Iyer et al., 2012; Waters et al., 2019).
In this study we decided to use different strategies to recover
the normal levels of miR-146a in the ALS aberrant cortical
astrocytes, comprising either the pre-miR-146a or compounds
recognized as immunoregulators. Our previous data evidenced
that glycoursodeoxycholic acid (GUDCA) and dipeptidyl vinyl
sulfone (VS) are effective in regulating inflammatory miRNAs
and counteracting the release of pro-inflammatory cytokines
(Fernandes et al., 2007; Vaz et al., 2015, 2019; Falcão et al.,
2017). Thus, we hypothesized that replenishment of miR-146a
in the cortical mSOD1 astrocytes toward normal levels could
abrogate their phenotypic aberrancies. If that happens, we will
avoid the release of neurotoxic factors leading to MN distress
and microglia activation (Nagai et al., 2007; Ajmone-Cat et al.,
2019; Gomes et al., 2019). Such polarized microglia release
TNF-α what in turn further contributes to astrocyte reactivity
and neurotoxicity (Liddelow and Barres, 2017). Therefore,
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restoration of the mSOD1 astrocyte steady-state phenotype
will facilitate homeostatic balance recovery. This is important,
once astrocyte-microglia crosstalk regulation or deregulation
determines neuronal functions and dysfunctions (Jha et al.,
2018). Actually, elimination of IL-1α, TNF-α, and C1q in the
mSOD1 mice, extended their survival (Guttenplan et al., 2020),
highlighting astrocyte reactivity and microglia activation as
therapeutic targets to prevent neurodegeneration in ALS.
In this work we used the cortical astrocytes isolated
from 7-day-old mSOD1 mice and cultured for 13 DIV,
that were transfected with pre-miR-146a or treated with the
immunomodulators GUDCA and VS, to test their ability to
abolish miR-146a downregulation. Astrocyte reactivity markers
usually characterizing their aberrant phenotype, together with
the Ca2+ overload (Kawamata et al., 2014), were assessed
with or without treatments. In addition, we evaluated the
potential neuroprotective and anti-inflammatory properties of
the secretome from treated astrocytes vs. the untreated ones,
using the mouse NSC-34 MN-like cell line produced from the SC
and the N9 microglial cell line from the brain. We explored the
expression of synaptic and axonal genes in MNs, iNOS and TNF-
α genes in microglia, as well as cell death by apoptosis, fibroblast
growth factor receptors (FGFR) 1 and 3 mRNAs, miR-146a and
proteomics in both cell types.
Our study is the first targeting the depressed levels of miR-
146a in cortical ALS astrocytes toward its restoration, with
ensuing data highlighting that both pre-miR-146a and VS may
represent new therapeutic ALS strategies to reestablish astrocyte
neuroprotection and microglia/MN homeostatic balance. Revival
of disease-specific cortical astrocytes in ALS was found to be
associated to the replenishment of miR-146a.
MATERIALS AND METHODS
Ethics Statement
The present study was performed in accordance with the
European Community guidelines (Directives 86/609/EU
and 2010/63/EU, Recommendation 2007/526/CE, European
Convention for the Protection of Vertebrate Animals used for
Experimental or Other Scientific Purposes ETS 123/Appendix
A) and Portuguese Laws on Animal Care (Decreto-Lei 129/92,
Portaria 1005/92, Portaria 466/95, Decreto-Lei 197/96, Portaria
1131/97). All the protocols used in this study were approved
by the Portuguese National Authority (General Direction of
Veterinary) and the Ethics Committee of the Instituto de
Medicina Molecular João Lobo Antunes (IMM) from Faculty of
Medicine, University of Lisbon, Portugal. Every effort was made
to minimize the number of animals used and their suffering,
according with the 3R’s principle.
Transgenic SOD1-G93A Mouse Model
Transgenic B6SJL-TgN (SOD1-G93A)1Gur/J males (Jackson
Laboratory, no. 002726) overexpressing the human(h)SOD1
gene carrying a glycine to alanine point mutation at residue
93 (mSOD1) (Gurney, 1994) and B6SJLF1/J non-transgenic
wild type (WT) females were purchased from The Jackson
Laboratory (Bar Harbor, ME, United States). Maintenance and
handling took place at IMM animal house facilities, where a
colony was established. Mice were maintained on a background
B6SJL by breeding SOD1-G93A transgenic males with non-
transgenic females. Both males and females were used as
described by us (Gomes et al., 2020). Transgenic SOD1-G93A
mice were compared to aged-matched WT mice. All animals were
maintained on 12 h light/12 h dark cycle and received food and
water ad libitum. Average number of animals per cage was 4 to 5.
Primary Culture of Astrocytes
Astrocytes were isolated from the cerebral cortices of WT
and mSOD1 mice at postnatal day 7 (Gomes et al., 2019,
2020). Approximately, 2.0 × 105 cells/cm2 were plated on
tissue culture plates in culture medium [DMEM (Biochrom
AG, Berlin, Germany) supplemented with 11 mM sodium
bicarbonate (Merck, Darmstadt, Germany), 38.9 mM glucose, 1%
Antibiotic-Antimycotic solution (Sigma-Aldrich, St. Louis, MO,
United States) and 10% Fetal Bovine Serum (FBS) (Biochrom
AG)] and maintained at 37◦C in a humidified atmosphere of
5% CO2 until 13 DIV, with changing of the culture medium at
7 DIV and 10 DIV. Then, cells were used for the evaluation of
reactive and inflammatory mediators, with or without treatment
strategies. These cells previously showed a set of specific-
disease markers that were also found in symptomatic mice
(Gomes et al., 2019), highlighting an early presentation of
the mSOD1-associated disease phenotype in such neonatal
astrocytes. Moreover, the culturing for 13 DIV guarantees the
maturation of astrocytes, as we previously showed (Falcão et al.,
2005, 2006). To assess astrocyte paracrine signaling, secretomes
were collected from 13 DIV astrocytes, either modulated or not
(as next explained), and sEVs were isolated.
Modulation of Cortical Astrocyte
Aberrancies
At 12 DIV, cells were incubated with 50 µM GUDCA
(Calbiochem; Darmstadt, Germany) or 10 µM VS (synthetized
by the Medicinal Chemistry group from Instituto de Investigação
do Medicamento) (Falcão et al., 2017), and maintained
for further 24 h.
To downregulate miR-146a in WT astrocytes, we
transfected cells with 15 nM Anti-miRTM 146a inhibitor
(#AM10722, Ambion R©, Thermo Fisher Scientific, Waltham,
MA, United States) at 11 DIV. According with manufacturer’s
description, they are chemically modified single-stranded
oligonucleotides with a patented secondary structure that binds
and inhibits the endogenous miR-146a.
To upregulate miR-146a in depleted mSOD1 astrocytes, the
cells were transfected with 15 nM Pre-miRTM 146a Precursor
(#PM10722, Ambion R©), a chemically modified double-stranded
RNA designed to mimic the endogenous precursor miR-146a and
to ensure the uptake of the correct strand to the RISC complex.
The mature miR-146a sequence was 5′UGAGAACUGAAUUC
CAUGGGUU3′ (hsa-miR-146a-5p). Then, the oligonucleotides
were mixed with X-tremeGENETM HP DNA Transfection
Reagent (Sigma-Aldrich, St. Louis, MO, United States) in
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a proportion 2:1 and diluted in Opti-MEMTM (Thermo
Scientific, Waltham, MA, United States). The controls used
were the non-transfected WT and mSOD1 cells treated only
with X-tremeGENETM HP DNA Transfection Reagent diluted
in Opti-MEMTM (mock control). To make sure that the
effect of miRNA-146a transfection in cells was due to its
specificity, we also transfected WT cells with 15 nM of
Anti-miR Negative Control and mSOD1 ones with 15 nM
Pre-miR Negative Control (Ambion R©). Results from mock
controls, and respective Anti-miR Negative Control and Pre-
miR Negative Control, were similar, validating the miR-146a
specificity (Supplementary Table 1). After 12 h, medium
was changed [DMEM supplemented with 11 mM sodium
bicarbonate, 38.9 mM glucose, 1% FBS sEVs-depleted and 1%
Antibiotic-Antimycotic solution] and maintained for 24 h. To
evaluate which alterations in astrocyte phenotype treated with VS
involved miR-146a regulation, we transfected WT astrocytes with
15 nM anti-miR-146a inhibitor at 11 DIV. After 12 h the medium
was changed, and the VS compound was added. The cells were
maintained in culture for further 24 h.
Culture of NSC-34 MN-Like Cells and
Treatment With Astrocyte-Derived
Secretome
In the present study we used the neuroblastoma hybrid
cell line NSC-34 expressing the human SOD1 WT. These
cells, produced by the fusion of MNs from mouse embryos
with mouse neuroblastoma cells N18TG2 (Cashman et al.,
1992), were shown to reproduce many features of MNs when
differentiated and maturated, and have been used to assess
neurotoxicity/neuroprotection (Maier et al., 2013; Vaz et al.,
2015), including astrocyte-induced neurodegeneration (Benkler
et al., 2013). As before, we decided to use these cells given our
previous experience with them (Vaz et al., 2015; Pinto et al.,
2017; Gomes et al., 2019) and considering the limitations of
primary spinal MN cultures, and the immature phenotype of
those generated from embryonic stem cells or from induced
pluripotent stem cells (Ho et al., 2016; Bucchia et al., 2018).
NSC-34 cells were cultured in Poly-D-lysine coated culture
plates at a density of 5 × 104 cells/ml and maintained
for 48 h in the proliferation media [DMEM high glucose,
w/o pyruvate, supplemented with 10% of FBS and 1% of
penicillin/streptomycin, and geneticin sulfate (G418, 0.5 mg/ml)
for selection], and then for additional 4 DIV in the differentiation
media [DMEM-F12 plus FBS (1%), non-essential amino acids
(1%) and penicillin/streptomycin (1%)], as previously described
(Vaz et al., 2015). Media from the differentiated NSC-34 cells
was removed and the cells incubated for 48 h with an equivalent
volume of the secretome derived from untreated astrocytes and
from pre-miR-146a and VS treated cells.
N9-Microglia Cell Culture and Treatment
With Astrocyte-Derived Secretome and
sEVs
Mouse microglial N9 cell line results from the immortalization
of microglia isolated from the cortex of CD1 mouse embryos
(Righi et al., 1989). This cell line shows properties that
are analogous to primary cultures of microglia, such as
migration, phagocytosis, and inflammation-related features
(Fleisher-Berkovich et al., 2010), and respond similarly to
lipopolysaccharide (LPS)-induced activation (Nikodemova and
Watters, 2011; Cunha et al., 2016).
N9 microglial cells were plated on uncoated culture plates at
a density of 1 × 105 cells/ml and maintained for 24 h in the
culture medium [RPMI media (Sigma-Aldrich, St. Louis, MO,
United States) supplemented with 10% FBS, 1% L-glutamine, and
1% antibiotic penicillin/streptomycin (1%), all from Biochrom
AG, Berlin, Germany], as usual in our laboratory (Cunha et al.,
2016; Pinto et al., 2017; Vaz et al., 2019). Then, culture media
were removed, and the cells incubated for 24 h with an equivalent
volume of the secretome derived from untreated astrocytes and
from pre-miR-146a and VS treated cells. Secretome contains
soluble factors and vesicular fractions as sEVs, essentially
containing miRNAs (Pinho et al., 2020). We showed that sEVs
were preferentially collected by microglia than by MNs, when in
coculture (Pinto et al., 2017). To assess whether the treatment
of astrocytes with pre-miR-146a or with VS would influence the
number of sEVs engulfed by the N9 microglia, we incubated
the isolated sEVs with microglia for 24 h. Subsequently, we
assessed the influence of those sEVs in shifting the inflammatory
state of microglia.
sEV Isolation, Characterization, and
Labeling
sEVs were isolated from the secretome of WT and mSOD1
astrocytes, using the process implemented in our lab (Pinto et al.,
2017). Briefly, the culture media was centrifuged at 1,000 g for
10 min to remove cell debris. After that, the supernatant was
centrifuged at 16,000 g to separate large extracellular vesicles
(lEVs, size 1,000 nm) and, the recovered supernatant was passed
into a 0.22 µM filter and further centrifuged in the Ultra L-XP100
centrifuge (Beckman Coulter Inc., CA, United States) at 100,000 g
to pellet sEVs, as we previously detailed (Pinto et al., 2017).
Characterization of sEVs in terms of shape was performed using
Negative-Staining Transmission Electron Microscopy (Jeol Jem
1400 TEM 120 kV, Tokyo, Japan). Concentration and size of sEVs
were evaluated by Nanoparticle tracking analysis (NTA) using
the Nanosight (model LM10-HSBF, Malvern, United Kingdom).
Expression of alix and flotillin-1 was assessed by Western blot
analysis, using 30 µg of total protein (antibodies are indicated
in the Supplementary Table 2). To evaluate miRNA cargo, the
final pellet containing sEVs was resuspended in lysis buffer, and
the RNA extracted as explained below.
To monitor the incorporation of astrocyte-derived sEVs
by N9 microglia, the sEVs were labeled with the PKH67
Fluorescent Linker Kit (Sigma Aldrich) in accordance with
manufacturer specifications, resuspended in DMEM with 1%
penicillin/streptomycin and added to N9 microglia cultures.
Immunocytochemistry
At 13 DIV, astrocytes were fixed with 4% paraformaldehyde
and immunofluorescence staining performed as published
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(Gomes et al., 2019). Briefly, cells were incubated overnight at
4◦C with GFAP (listed in the Supplementary Table 2). In the
following day, cells were incubated with secondary antibody, also
referred in the Supplementary Table 2. Cell nuclei were stained
with Hoechst 33258 dye and then mounted onto uncoated slides
using PBS-Glycerol (1:1). Fluorescence was visualized using an
AxioCam HR camera adapted to an AxioScopeA1 microscope.
Fluorescence of ten random microscopic fields were acquired
per sample using Zen (blue edition, 2012, Zeiss) software and
the number of positive cells above a determined threshold or
fluorescence per total number of cells was quantified. Area of
sEVs labeled with PKH67 was determined per total number of
PKH67-positive cells.
Western Blot Analysis
Cell lysis and protein isolation was made as usual in our
lab (Gomes et al., 2019), and we used the protein assay kit
(Bio-Rad, Hercules, CA, United States) to assess the protein
concentration as manufacturer’s specifications. Then, equal
amounts of protein were subjected to SDS-PAGE and transferred
to a nitrocellulose membrane. After blocking with 5% (w/v)
non-fat milk solution, nitrocellulose membranes were incubated
overnight at 4◦C with primary antibodies (depicted in the
Supplementary Table 2). In the following day, secondary
antibodies conjugated to horseradish peroxidase were used
(Supplementary Table 2). The chemiluminescent detection was
performed after membrane incubation with LumiGLO R© (Cell
Signaling). The relative intensities of protein bands were analyzed
using the Image LabTM analysis software, after scanning with
ChemiDocXRS, both from Bio-Rad Laboratories (Hercules, CA,
United States). Results in cells were normalized to β -actin
expression levels.
RT-qPCR
Cellular RNA was isolated using TripleXtractor Reagent (GRISP,
Porto, Portugal) (Gomes et al., 2019). For astrocyte-derived sEVs,
RNA was extracted using miRNeasy Mini kit (Qiagen, Hilden,
Germany). Quantification was performed using Nanodrop ND-
100 Spectrophotometer (NanoDrop Technologies, Wilmington,
DE, United States).
For gene expression, cellular RNA was converted to
complementary DNA (cDNA) using GRS cDNA Synthesis
Mastermix Kit (GRISP). Reverse transcriptase quantitative PCR
(RT-qPCR) was accomplished using Xpert Fast SYBR Green Blue
(GRISP) and the following optimized conditions: 94◦C for 2 min
followed by 40 cycles at 95◦C for 0.05 min and 62◦C for 0.3 min.
To verify the specificity of the amplification, a melt-curve analysis
was performed immediately after the amplification protocol.
Non-specific products of PCR were not found in any case. β-actin
was used as an endogenous control to normalize the expression
levels. Primer sequences are listed in the Supplementary Table 3.
Expression of miRNA-146a (5′ UGAGAACUGAAUUCCAU
GGGUU 3′) was assessed in cells and sEVs by RT-qPCR. After
RNA quantification, cDNA conversion for miRNA quantification
was performed with the miRCURY LNATM RT Kit (Qiagen),
using 5 ng total RNA for cells and 10 ng for sEVs. The
PowerUpTM SYBRTM Green Master Mix (Applied Biosystems,
Life Technologies) was used in combination with pre-designed
primers. The reaction conditions consisted of polymerase
activation/denaturation and well-factor determination at 95◦C
for 10 min, followed by 50 amplification cycles at 95◦C for 10 s
and 60◦C for 1 min (ramp-rate of 1.6◦/s). SNORD110 (reference
gene) was used as an endogenous control and to normalize the
expression levels in cells. Both SNORD110 and spike-in were
used as endogenous controls and geometric mean from both
were calculated to normalize the expression levels in sEVs. RT-
qPCR was accomplished on a QuantStudio 7 Flex Real-Time PCR
System (Applied Biosystems, Life Technologies) and 384-well
plates were used. Relative mRNA/miRNA concentrations were
calculated using the 2−11CT method.
Cell Death Determination
Phycoerythrin-conjugated Annexin V (Annexin V-PE) and 7-
amino-actinomycin D (7-AAD; Guava Nexin R© Reagent, no.
4500-0450, Millipore) were used to determine the percentage
of viable (Annexin V-PE and 7-AAD negative), early apoptotic
(Annexin V-PE positive and 7-AAD negative), and late
apoptotic/necrotic (Annexin V-PE and 7-AAD positive) cells
by flow cytometry, as described (Gomes et al., 2020). After
incubation, cells were trypsinized and added to the cells already
detached in the culture medium. After centrifugation, the pellet
of cells was resuspended in PBS containing 1% bovine serum
albumin. Then, they were stained with Guava Nexin Reagent
according to manufacturer’s instructions and analyzed on a
Guava easyCyte 5HT flow cytometer (Guava Nexin R© Software
module, Millipore).
Ca2+ Imaging in Astrocytes and Analysis
Astrocyte Ca2+ imaging was performed as previously reported
(Morais et al., 2017). Briefly, the suspension of astrocytes was
plated on µ-slide 8 well chamber slide (Ibidi R©, Gräfelfing,
Germany) coated with 10 µg/ml of poly-D-lysine. At 13 DIV,
cells were incubated at 37◦C for 45 min with the Ca2+ sensitive
fluorescent dye fura-2 acetoxymethyl ester (Fura-2AM; 5 mM;
Calbiochem, Darmstadt, Germany). After three washes with
artificial cerebrospinal fluid (aCSF: NaCl 125 mM, KCl 3 mM,
NaH2PO4 1.25 mM, CaCl2 2 mM, MgSO4 2 mM, D(C)-
glucose 10 mM and HEPES 10 mM; pH 7.4 adjusted with
NaOH) cells were positioned on an inverted epifluorescent optics
microscope (Axiovert 135TV, Zeiss, Germany) with a xenon
lamp and band-pass filters of 340 and 380 nm wavelengths.
Cells were continuously perfused with aCSF (with or without
added compounds) at 1.5 ml/s and visualized with a 40x oil-
immersion objective (Zeiss). The responses were recorded by a
ratiometric method, in which image pairs were obtained every
250 ms by exciting the preparations at 340 and 380 nm, since
Fura-2 has an absorbance at 340 nm if bound to calcium,
and at 380 nm if not, while the emission wavelength was
maintained at 510 nm. The magnitude of the changes in
the emission fluorescence of Fura-2 was taken as a measure
of the changes in intracellular Ca2+ concentration (Ca2+T
amplitude).
Excitation wavelengths were changed through a high-
speed wavelength switcher, Lambda DG-4 (Sutter Instrument,
Novato, CA, United States). An estimation of intracellular
Ca2+ concentration was given by the ratio between the
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emissions derived from the two excitation wavelengths of Fura-
2 (R340/380). All data were recorded by a cooled CCD camera
(Photometrics CoolSNAP fx) and processed and analyzed by
MetaFluor software (Universal Imaging, West Chester, PA,
United States). During the first 5 min of the trial, baseline
Ca2+ levels were established. Addition of glutamate, as the
stimulating agent (100 µM), was performed after those first
5 min corresponding to the baseline, and the cell response
recorded in the next 10 min, this completing 15 min of total time
recording. Representative videos of intracellular Ca2+ changes
were obtained with the MetaFluor Analyst and using AVI Creator
and Movie Maker software programs.
The frequency of Ca2+ transients was determined with
MATLAB and Statistics Toolbox Release 2016a, The MathWorks,
Inc. (Natick, MA, United States), as previously described
(Martins et al., 2020). In the first 5 min of the experiment, a
baseline was obtained. Mean and standard error of the mean
(SEM) of all data recorded by each cell were obtained.
Ca2+ transient was considered valid when fura-2 excitation
wavelength at 340 nm and 380 nm (F340/380) ratio was
higher than the mean of baseline values plus 5 times the
SEM. In addition, the normalized ratio was considered when
above this margin for more than 5 s. For every region of
interest, the peak of each transient, as well as the occurrence of
transients, were recorded.
Proteomics
Mass Spectrometric (MS) Analysis
The following cellular pellets were collected for proteomic
analysis: (i) mSOD1 astrocytes, transfected or not with
pre-miR-146a; (ii) naïve microglia; and (iii) WT motor neurons
after incubation with mSOD1 astrocytic secretome (± pre-miR-
146a). The cellular pellets were collected by trypsinization for
5 min, washed with PBS and immediately stored at −80◦C.
Each sample resulted from a pool of three biological replicates
(cells isolated from different mice that were pooled down
and sent for analysis at EMBL Proteomics Core Facility in
Heidelberg, Germany. Samples were subjected to an in-solution
tryptic digest using a modified version of the Single-Pot Solid-
Phase-enhanced Sample Preparation (SP3) protocol (Moggridge
et al., 2018). To this end, samples were added to Sera-Mag
Beads (Thermo Scientific) in 10 µl 15% formic acid and 30 µl
of ethanol. Binding of proteins was achieved by shaking for
15 min at room temperature. SDS was removed by 4 subsequent
washes with 200 µl of 70% ethanol. Proteins were digested
overnight at room temperature with 0.4 µg of sequencing grade
modified trypsin (Promega) in 40 µl Hepes/NaOH, pH 8.4 in
the presence of 1.25 mM TCEP and 5 mM chloroacetamide
(Sigma-Aldrich). Beads were separated, washed with 10 µl of
an aqueous solution of 2% DMSO and the combined eluates
were dried down. Peptides were reconstituted in 10 µl of
H2O and reacted for 1 h at room temperature with 80 µg of
TMT10plex (Thermo Scientific) (Moggridge et al., 2018) label
reagent dissolved in 4 µl of acetonitrile. Then, they were reacted
with TMT-labeling reagent. 5% of each sample were mixed,
purified by a reverse phase clean-up step (OASIS) and analyzed
on a LUMOS system using a 1 h gradient. Calculated TMT
ratios were used to adjust sample volumes to achieve a 1:1
ratio. The combined samples were subjected to a high pH offline
fractionation yielding 12 fractions, each of those analyzed on
a 2 h gradient on Orbitrap Fusion Lumos mass spectrometer
(Thermo Scientific). Peptides were separated using an UltiMate
3000 nano RSLC system (Dionex) equipped with a trapping
cartridge (Precolumn; C18 PepMap 100, 5 mm, 300 µm i.d.
×5 µm, 100 A◦) and an analytical column (Acclaim PepMap
100. 75 cm × 50 cm C18, 3 mm, 100 Å) connected to a
nanospray-Flex ion source. The peptides were loaded onto the
trap column at 30 µl per min using solvent A (0.1% formic
acid) and eluted using a gradient from 2 to 40% Solvent B (0.1%
formic acid in acetonitrile) over 2 h at 0.3 µl per min. The
Orbitrap Fusion Lumos was operated in positive ion mode with
a spray voltage of 2.4 kV and capillary temperature of 275◦C
to analyze the peptides. MS spectra with a mass range of 375–
1.500 m/z were acquired in profile mode using a resolution
of 120.000 [maximum fill time of 50 ms or a maximum of
4 × 105 ions (automatic gain control, AGC)]. Fragmentation
was triggered for 3 s cycle time for peptide like features with
charge states of 2–7 on the MS scan (data-dependent acquisition).
Precursors were isolated using the quadrupole with a window of
0.7 m/z and fragmented with a normalized collision energy of
38. Fragment mass spectra were acquired in profile mode and a
resolution of 30,000 in profile mode. Maximum fill time was set
to 64 ms or an AGC target of 1e5 ions). The dynamic exclusion
was set to 45 s.
Raw MS Data and Analysis
Acquired data were analyzed using IsobarQuant (Franken et al.,
2015), Mascot V2.4 (Matrix Science) and a reverse UniProt
FASTA Mus musculus (UP000000589) database, including
common contaminants. The following modifications were
considered: Carbamidomethyl (C, fixed), TMT10plex (K,
fixed), Acetyl (N-term, variable), Oxidation (M, variable) and
TMT10plex (N-term, variable). The mass error tolerance for
full scan MS spectra was set to 10 ppm and for MS/MS spectra
to 0.02 Da. A maximum of 2 missed cleavages were allowed.
A minimum of 2 unique peptides with a peptide length of at
least seven amino acids and a false discovery rate below 0.01
was required on the peptide and protein level (Savitski et al.,
2015). 9083 proteins were identified, from which 6748 proteins
were quantified. The raw output files of IsobarQuant were
processed using the R programming language (R Development
Core Team, 2020). As a quality filter, we only considered proteins
that were quantified with at least two unique peptides. Raw TMT
reporter ion intensities [Average expression (signal_sum)] were
normalized using variance stabilization normalization (Huber
et al., 2002). Differential expression was evaluated by computing
the respective ratio of normalized TMT signals (additional
parameters are indicted in Supplementary Tables 4–6). The
proteins identified as hits were then classified by their link to
biological processes using Gene Ontology (GO) annotation
in Scaffold. Bioinformatic analysis of protein molecular
function was done by using PANTHER Classification System
(Version 16.0, released 2020-12-01) (Mi et al., 2021). Functional
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classification of gene lists for Mus musculus were examined using
PANTHER Protein Class ontologies. MS proteomics data have
been deposited to the ProteomeXchange Consortium via the
PRIDE database1 (Perez-Riverol et al., 2019) partner repository
with the dataset identifier PXD024294.
Statistical Analysis
Results of at least three independent experiments were expressed
as mean values ± SEM. Results of untreated or treated mSOD1
astrocytes, astrocyte-derived secretome and astrocyte-derived
sEVs were related to respective untreated WT samples. Since
we always compared at least three groups, we determined the
differences between them by using one-way ANOVA followed
by Bonferroni post hoc test. Statistical analysis was performed
using GraphPad PRISM 7.0 (GraphPad Software, San Diego, CA,
United States) p < 0.05 was considered as statistically significant.
RESULTS
VS Is More Competent Than GUDCA in
Restoring miR-146a Expression and
Counteracting mSOD1 Astrocytic
Aberrancies
In the present study, we first assessed whether our promising
immunomodulators GUDCA and VS were able to restore the
normal levels of miR-146a in the cortical mSOD1 astrocytes
isolated from the 7-day-old mSOD1 mice and cultured for 13
DIV. Such miR-146a was found downregulated in cells presenting
decreased gene and protein levels of GFAP, and upregulated
gene expression of vimentin, Cx43, S100B and HMGB1 (Gomes
et al., 2019). This miR-146a was found to fine tune Toll-like
receptors and cytokine signaling (Taganov et al., 2006) and to
be a key regulator of astrocyte-mediated inflammatory response
(Iyer et al., 2012). Though miR-146 has at least 488 predicted
targets, as reviewed in Brites (2020), we decided to investigate
whether miR-146a inhibited two of its recognized target genes,
the interleukin-1 receptor-associated kinase (IRAK) 1 and TNF
receptor-associated factor (TRAF) 6 (Iyer et al., 2012; Saba
et al., 2014). Actually, we have found that both Irak1 and
Traf6 transcripts were upregulated in mSOD1 cortical astrocytes
(Gomes et al., 2019).
We confirmed that miR-146a was indeed downregulated in
the mSOD1 cortical astrocytes (p < 0.05), while their target
genes IRAK1 and TRAF6 were upregulated (Figures 1A–C,
at least p < 0.05). We also validated that the expression of
the aberrant-associated genes was deregulated (Figures 1D–
J, at least p < 0.05), attesting the characteristic phenotype
previously established (Gomes et al., 2019). From the treatment
of cells with either GUDCA or VS, only the later showed to
effectively upregulate miR-146a and downregulate IRAK1 and
TRAF6 (Figures 1A–C, at least p < 0.01), as well as to restore
GFAP protein levels (Figures 1E,F). Interestingly, both GUDCA
and VS abrogated the increased levels of vimentin and Cx43
1http://www.ebi.ac.uk/pride/archive/projects/PXD024294
(Figures 1G,H, at least p < 0.05), and were not toxic to the
cells through the induction of early or late apoptosis, as depicted
in Supplementary Figure 1. VS was again the most efficient in
downregulating S100B and HMGB1 gene expression toward the
WT levels (Figures 1I,J at least p < 0.05). Thus, VS demonstrated
to have a broader reparative ability than GUDCA in recovering
miR-146a expression and in counteracting the mSOD1 astrocytes
associated reactive markers.
Treatment of mSOD1 Astrocytes With
Pre-miR-146a Abolishes Their
Phenotypic Aberrancies
To assess whether miR-146a downregulation in cortical
astrocytes isolated from mSOD1 pups was a player in the
deregulated astrocyte polarization, we decided to transfect the
cells with pre-miR-146a, as indicated in Material and Methods
section, and to evaluate the post-treatment signature of the cells.
We noticed that the mSOD1 astrocytes were more sensitive
to the transfection process than the WT cells, as judged by the
loss of viable cells (p < 0.05) due to an increase of cell late
apoptosis (p < 0.01) (Supplementary Figure 2). Interestingly,
such features disappeared in cells transfected with pre-miR-146a,
reinforcing the regulatory role of miR-146a in stress/immune-
associated stimuli. A 3-fold increase in the levels of miR-146a
in the mSOD1 astrocytes was achieved by the transfection with
the pre-miR-146a, with values close to those presented by WT
astrocytes (Figure 2A, p < 0.001), and its target genes IRAK1
(Figure 2B, p < 0.05) and TRAF6 (Figure 2C, p < 0.001) were
reduced near to normal values.
Then, we investigated if the restoration of miR-146a levels
was able to attenuate the aberrant phenotype of mSOD1
astrocytes. We verified that such treatment not only restored
the gene control values of S100B (Figure 2D, p < 0.001),
Cx43 (Figure 2E, p < 0.01), vimentin (Figure 2F, p < 0.05),
and HMGB1 (Figure 2G, p < 0.05), but also recovered the
GFAP protein expression levels (Figures 2H–K, p < 0.05).
Besides, genetic upregulation of miR-146a restored the protein
levels of S100B (Figures 2J,L, p < 0.001) and of Cx43
(Figures 2J,M, p < 0.01) toward the control values, attesting
that the reduction of miR-146a expression may contribute to the
cortical astrocyte aberrancies associated to the ALS disease and to
MN degeneration.
To better understand the upregulation of miR-146a in the
attenuation of ALS astrocyte-aberrancies and its potential targets
we performed proteomic analysis. Data identified 10 hits after
the treatment of mSOD1 astrocytes with pre-miR-146a vs.
the untreated cells (Figure 2N and Supplementary Table 4).
The increase of the neutrophil cytosol factor 1 encoded by
the gene Ncf1 may prevent the immune response of mSOD1
challenged astrocytes (Holmdahl et al., 2016; Zhao et al., 2017).
In the same way, the upregulated zinc finger and BTB domain-
containing 10, encoded by Zbt10, and the downregulated non-
histone chromosomal protein HMG-17, encoded by Hmgn2, may
turn the neurotoxic into a neuroprotective astrocyte phenotype.
Increased expression of proteins encoded by the genes Chd8,
Lrch4, Thg1l, Gtpbp6, and Ezh1, involved in gene transcription
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FIGURE 1 | mSOD1 astrocytic aberrancies are more efficiently counteracted by VS than by GUDCA. Astrocytes were isolated from the cortex of SOD1-G93A
(mSOD1) and wild type (WT) mice pups at 7-day-old and cultured for 13 days in vitro. Treatment with glycoursodeoxycholic acid (GUDCA) or dipeptidyl vinyl sulfone
(VS) was performed in mSOD1 astrocytes. RT-qPCR analysis of (A) miRNA(miR)-146a, (B) interleukin-1 receptor associated kinase-1 (IRAK1) and (C) TNF receptor
associated factor 6 (TRAF6), (G) vimentin, (H) connexin-43 (Cx43), (I) S100 calcium-binding protein B (S100B) and (J) high mobility group box 1 (HMGB1) was
performed. (D) Representative images of astrocytes stained with glial fibrillary acidic protein (GFAP, in green) by immunocytochemistry and (E) quantification of
GFAP-positive cells. Cell nuclei were stained with Hoechst dye (blue). (F) GFAP performed by Western blot analysis and the representative results from one blot are
shown. Expression of β-actin was used as an endogenous control for Western Blot and RT-qPCR assays. SNORD110 was used as a reference gene for (A) analysis.
Results are mean (±SEM) fold change vs. WT astrocytes from at least four independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. WT astrocytes;
#p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.0001 vs. untreated mSOD1 astrocytes. One-way ANOVA followed by Bonferroni post hoc test was used. Scale
bar represents 20 µm.
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FIGURE 2 | miR-146a upregulation successfully recovers GFAP expression and counteracts deregulated reactive markers in mSOD1 astrocytes. Astrocytes were
isolated from the cortex of SOD1-G93A (mSOD1) and wild type (WT) mice with 7-day-old and cultured for 13 days in vitro. Transfection with pre-miR-146a was
performed in mSOD1 astrocytes. RT-qPCR analysis of (A) miRNA(miR)-146a, (B) interleukin-1 receptor associated kinase-1 (IRAK1) and (C) TNF receptor
(Continued)
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FIGURE 2 | Continued
associated factor 6 (TRAF6), (D) S100 calcium-binding protein B (S100B), (E) connexin-43 (Cx43), (F) vimentin, and (G) high mobility group box 1 (HMGB1) was
performed. (H) Representative images of astrocytes stained with glial fibrillary acidic protein (GFAP, in red) by immunocytochemistry and (I) quantification of
GFAP-positive cells. Cell nuclei were stained with Hoechst dye (blue). Protein expression of (K) GFAP, (L) S100B, and (M) Cx43 was performed by Western blot
analysis and (J) representative results from one blot are shown. Expression of β-actin was used as an endogenous control for Western Blot and RT-qPCR assays.
SNORD110 was used as reference gene for (A) analysis. Results are mean (±SEM) fold change vs. WT astrocytes from at least four independent experiments.
*p < 0.05 and **p < 0.01 vs. WT astrocytes; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. untreated mSOD1 astrocytes. One-way ANOVA followed by Bonferroni
post hoc test was used. Scale bar represents 20 µm. (N) MA plot (left) was obtained by comparison of the proteomic profiles of pre-miR-146a treated mSOD1
astrocytes and the untreated ones. Here, x axis is the mean log2 intensity (fold change) of each protein between two profiles (A-value) and y axis is the average
expression (signal_sum) of protein intensities (M-value). Summary tables (right panels) show the hits and their classification according to biological processes using
PANTHER Classification System, as indicated in methods.
and epigenetic modifications, suggest a role of miR-146a in the
accurate control of stage-specific gene activities required for
proper astrocyte function. Upregulation of the pregnancy zinc
protein, encoded by Pzp and of the guanine nucleotide exchange
factor for Rab5 (the homolog Als2cl) by pre-miR-146a may
contribute to prevent mSOD1 pathology, since the first inhibits
the aggregation of misfolded proteins (Cater et al., 2019) and
the later controls endosome dynamics, thus favoring mSOD1
clearance by sEVs (Hessvik and Llorente, 2018) and autophagy
(Otomo et al., 2012).
Overall, our data highlight miR-146a upregulation as a
promising therapeutic strategy to restore the steady-state profile
of ALS astrocytes and suggest a new mechanism of action of VS as
upregulating miR-146a in defective mSOD1 cortical astrocytes.
Anti-miR-146a Transfection in WT
Astrocytes Reproduces mSOD1 Cortical
Astrocyte Aberrancies, Which Are
Prevented by VS
To explore if the efficacy of VS in counteracting the aberrant
profile of astrocytes was mediated through its direct action on
miR-146a, we downregulated miR-146a expression in astrocytes
isolated from the brain cortex of B6SJLF1/J non-transgenic WT
mice. We confirmed that the transfection of cortical astrocytes
with anti-miR-146a, after being isolated from 7-day-old WT
mice and cultured for 13 days, led to a 2-fold decrease in the
expression of miR-146a (Figure 3A, p < 0.01). In conformity,
IRAK1 and TRAF6 gene expression levels were overexpressed
(Figures 3B,C). Such immune deregulation was translated into
the typical astrocyte ALS fingerprint, i.e., low GFAP protein and
increased S100B, vimentin and Cx43 mRNAs (Figures 3D–H), as
observed in mSOD1 cortical astrocytes.
Then, we wonder whether VS would be able to invert the
signature of ALS cells produced by miR-146a inhibition. Addition
of VS was in fact able to restore the WT astrocyte profile even
after the anti-miR-146a transfection. Indeed, WT astrocytes co-
treated with VS and anti-miR-146a presented the steady-state
signature of healthy cells for miR-146a and its targets IRAK1
and TRAF6 gene expression levels (Figures 3A–C), as well as
for GFAP, S100B and vimentin (Figures 3D–G). Interestingly,
VS was not as effective as pre-miR-146a in abrogating the
elevated levels of Cx43 derived from the anti-miR-146a treatment
in WT astrocytes.
Data suggest that miR-146a downregulation is associated with
a pathological ALS astrocyte signature, which can be rescued
through immunomodulation with pre-miR-146 or by addition of
VS, reinforcing depleted miR-146a as a promising target for the
restoration of cell homeostasis in the brain cortex.
VS Counteracts High Intracellular Ca2+
in mSOD1 Astrocytes, but Only
Pre-miR-146a Prevents Enhanced
Frequency and Amplitude of
Glutamate-Induced Ca2+ Transients
Among the several toxic factors secreted by mSOD1 astrocytes
is the excess of Ca2+ release that was found to contribute to
the pathogenesis of ALS (Kawamata et al., 2014). Though that
Ca2+ signals are fundamental for the regulation of intracellular
signaling, as well as for vesicular secretion processes in astrocytes,
their acute and chronic changes in response to brain injury were
associated to dysregulated astrocyte-neuron communication
(Vardjan et al., 2017). Evidence showed that aberrant Ca2+ signals
in reactive astrocytes are implicated in the onset, progression
and severity of neurodegenerative diseases (Shigetomi et al.,
2019). Here, we intended to explore the intracellular calcium
dysregulation in ALS astrocytes and the ability of pre-miR-
146a and VS to prevent such abnormality and restore the
neuroprotective profile of astrocytes.
We evaluated intracellular Ca2+ dynamics by live-cell imaging
using the fluorescent dye Fura-2. Ca2+ signaling was measured
without any stimulation (baseline) or in response to glutamate
addition, which is a trigger of free cytoplasmic Ca2+ oscillations
(Cornell-Bell et al., 1990) and known to be extracellularly elevated
in ALS (Yamanaka and Komine, 2018).
Ca2+ signaling was assessed by the fluorescence intensity
response of Fura-2 after consecutive stimulation at 340
and 380 nm and quantified in individual cells the ratio
between the two responses (R340/380) (Figure 4 and
Supplementary Videos 1–4). mSOD1 astrocytes revealed
a significant increase of the basal Fura-2 340/380 ratio in
(p < 0.01) when compared with matched vs. WT astrocytes
(Figures 4A,B,E,F and Supplementary Videos 1, 2). Treatment
with VS restored the WT values (p < 0.0001), but not pre-
miR-146a upregulation (Figures 4A,B,G,H and Supplementary
Videos 3, 4, respectively).
Treatment of astrocytes with 100 µM glutamate produced
a higher frequency of Ca2+ transients in mSOD1 astrocytes, as
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FIGURE 3 | VS rescues GFAP levels and abolishes vimentin- and S100B-associated reactivity induced by the miR-146a inhibitor in WT astrocytes. Astrocytes were
isolated from the cortex of wild type (WT) mice with 7-day-old and cultured for 13 days in vitro. Transfection with anti-miR-146a followed by treatment with dipeptidyl
vinyl sulfone (VS) was performed in these cells. RT-qPCR analysis of (A) miRNA(miR)-146a, (B) interleukin-1 receptor associated kinase-1 (IRAK1), (C) TNF receptor
associated factor 6 (TRAF6), (F) S100 calcium-binding protein B (S100B), (G) vimentin and (H) connexin-43 (Cx43) was performed. SNORD110 was used as
reference gene for (A) analysis and β-actin for (B,C,F–H) analysis. (D) Representative images of astrocytes stained with glial fibrillary acidic protein (GFAP, red) in red
by immunocytochemistry and (E) respective quantification of the GFAP-positive cells. Cell nuclei were stained with Hoechst dye (blue). Results are mean (±SEM) fold
change vs. untreated WT astrocytes from at least three independent experiments. **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. untreated WT astrocytes;
##p < 0.01, ###p < 0.001, and ####p < 0.0001 vs. WT astrocytes treated with anti-miR-146a. One-way ANOVA followed by Bonferroni post hoc test was used.
Scale bar represents 20 µm.
compared with the WT astrocytes (Figures 4C,E,F, p < 0.0001
and Supplementary Videos 5, 6). In the pre-miR-146a
transfected mSOD1 astrocytes the addition of glutamate
prevented the increased number of transient Ca2+ signaling
events observed in the non-modulated cells (Figures 4C,G,
p < 0.001 and Supplementary Video 7). A similar finding
was observed in the amplitude of Ca2+ waves, where a small,
but significant decrease occurred in glutamate-treated mSOD1
astrocytes previously transfected with pre-miR-146a, but not
with VS (Figures 4D,H, p < 0.01 and Supplementary Video 8),
supporting a delayed response of Ca2+ release in the mSOD1
astrocytes upregulated for miR-146a.
Results suggest that VS and pre-miR-146a differently regulate
intracellular Ca2+ load. In the absence of increased extracellular
glutamate, VS is a more promising strategy in sustaining
intracellular Ca2+ homeostasis. However, if excitotoxity is
predicted to occur, then pre-miR-146a treatment has advantage
over the use of VS to control Ca2+ dynamic dysregulation.
Overexpression of Pre-miR-146a in
mSOD1 Astrocytes Is Recapitulated in
Their Derived sEVs
Besides the paracrine influence of the Ca2+ signals derived
from reactive astrocytes, it is currently accepted that other
components of the astrocytic secretome contribute to
neurotoxicity and microglia activation in ALS, mainly due
to astrocytic-derived sEVs and their content in miRNAs and
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FIGURE 4 | VS reduces the upregulated intracellular Ca2+, while pre-miR-146a normalizes the number and amplitude of glutamate-induced Ca2+ transients in
mSOD1 astrocytes. Astrocytes were isolated from the cortex of SOD1-G93A (mSOD1) and wild type (WT) mice with 7-day-old and cultured for 13 days in vitro.
Transfection with pre-miR-146a or treatment with dipeptidyl vinyl sulfone (VS) was performed in mSOD1 astrocytes. Cells were incubated at 37◦C for 45 min with the
(Continued)
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FIGURE 4 | Continued
calcium (Ca2+) sensitive fluorescent dye fura-2 acetoxymethyl ester (Fura-2), followed by glutamate addition (100 µM). (A) Pseudocolored Fluo4 fluorescence
images in WT, untreated and treated-mSOD1 astrocytes show a prominent rise in intracellular Ca2+ and respective (B) changes in the baseline of Fura-2
fluorescence. The color code refers to the fluorescence ratio 340 nm/380 nm, with higher ratio reflecting higher intracellular Ca2+. (C) Summary plot of the frequency
of transients per minute and (D) the amplitude of the Ca2+ responses. Results are mean (±SEM) from at least 40 responsive cells from six independent experiments.
Representative profiles of normalized Ca2+ responses of at least 8 cells in (E) WT astrocytes and (F) mSOD1 astrocytes treated with (G) pre-miR-146a and (H) VS.
The first 300 s represents the changes of Fura-2 fluorescence in the baseline. The remaining 600 s refers to changes after glutamate addition. **p < 0.01 and
****p < 0.0001 vs. WT astrocytes; ##p < 0.01, ###p < 0.001, and ####p < 0.0001 vs. untreated mSOD1 astrocytes. One-way ANOVA followed by Bonferroni
post hoc test was used. Scale bar represents 20 µm.
misfolded/mutated proteins (Silverman et al., 2016; Ferrara
et al., 2018; Varcianna et al., 2019). Recently, we have shown that
astrocytes isolated from the SC and the brain cortex of mSOD1
mouse pups are depleted in miR-146a, miR-155 and miR-21
(Gomes et al., 2020).
In this sense, we next assessed if the sEVs isolated from
the mSOD1 astrocyte were depleted in miR-146a and whether
the treatment of the cells with pre-miR-146a or VS was able
to enrich the sEVs in such miRNA. We first characterized
the sEVs for the presence of characteristic proteins such as
Alix and Flotillin-1 (Figure 5A) and confirmed their cup-
shape morphology by transmission electron microscopy (TEM)
(Figure 5B), proving the efficiency of sEV isolation. Next, we
attested that the transfection of the astrocytes with pre-miR-
146 did not modified the number, size, or the concentration
of sEVs (Figures 5C–E), relatively to those from WT and
mSOD1 astrocytes. Interestingly, when assessed for miR-146a
cargo, we observed a 22-fold increase of miR-146a in sEVs
derived from the pre-miR-146a-treated astrocytes (Figure 5F,
p < 0.01). In contrast, despite the ability of VS to increase
the intracellular levels of miR-146a in the depleted mSOD1
astrocytes, it was unable to induce its integration in the secreted
sEVs from VS-treated astrocytes, as compared with the untreated
ones (Figure 5G).
From the data obtained we may conclude that only pre-miR-
146a treatment of mSOD1 astrocytes has beneficial consequences
in the active transfer of this miRNA into sEVs, thus re-
establishing paracrine signaling to recipient cells, and effects in
their target genes. We cannot, however, disregard that VS can
also have positive influence on the neighboring cells through
astrocyte-derived unidentified soluble factors.
Neuroprotective Strategies of mSOD1
Astrocytes by Pre-miR-146a or VS
Immunomodulation Involve Distinct
Signaling Pathways
Once mSOD1 astrocytes were shown to release neurotoxic factors
that lead to MN demise (Nagai et al., 2007; Gomes et al., 2019,
2020), we next decided to explore whether the effects produced
by pre-miR-146a or VS modulation in the cells would translate
into a more neuroprotective secretome.
To explore this issue, we used WT MNs given the reasons
explained in the Materials and Methods section, including our
expertise with these cells and previous data (Vaz et al., 2015;
Pinto et al., 2017; Gomes et al., 2019). We observed that
the increase of miR-146a in the WT MNs was only achieved
by the secretome from the mSOD1 astrocytes overexpressing
miR-146a (Figure 6A, p < 0.001). Despite the upregulation of
miR-146a in the mSOD1 astrocytes treated with VS (Figure 1A),
miR-146a was not enriched in sEVs isolated from the secretome
of VS-treated mSOD1 astrocytes (Figure 5G), or in WT MNs
treated with the secretome from VS-treated mSOD1 astrocytes
(Figure 6A). These findings suggest that soluble miR-146a may
have accounted for its rise in MNs, an issue that deserves future
studies for clarification.
Expression of the fibroblast growth factor receptor 1 (FGFR1)
and 3 (FGFR3) were found in neurons and associated to major
roles during neurodevelopment, namely in dendritogenesis
(Huang et al., 2017; Okada et al., 2019). We found that the
secretome from mSOD1 astrocytes induced the overexpression
of both receptors in MNs (Figures 6B,C). When modulated,
while that from VS-treated mSOD1 astrocytes did not
cause any alteration, the secretome from pre-miR-146a-
treated mSOD1 astrocytes sustained their levels close to
WT ones, a finding not achieved with VS. Transfection of
mSOD1 astrocytes with pre-miR-146a also prevented MN
death by early and late apoptosis processes (Figures 6D,E,
p < 0.05) induced by the secretome from the non-modulated
pathological cells. Only the early apoptosis was prevented
by the secretome from mSOD1 astrocytes previously treated
with VS (p < 0.01).
As depicted in Figures 6F–I, secretome from mSOD1
astrocytes decreased pre- and post-synaptic proteins
(synaptophysin and PSD-95, respectively), as well as proteins
involved in anterograde and retrograde axonal transport (kinesin
and dynein, respectively) (p < 0.05 for all). In this case, major
benefits were obtained by the VS treatment that markedly
upregulated the expression of all these genes (p < 0.001),
though the secretome from pre-miR-146a-treated mSOD1
astrocytes reversed the deficient PSD-95 gene expression and
that of the anterograde transport motor kinesin (p < 0.05).
To be sure that the effects observed in MNs were due to the
secretome from the VS-treated astrocytes and not to the presence
of the own compound in the secretome, we evaluated the
expression of PSD-95, kinesin and miR-146a in MNs exposed
to the media from untreated and VS-treated WT astrocytes.
Results showed no differences between such conditions
(Supplementary Figure 3). Overall, our findings evidence
that the treatment of mSOD1 astrocytes with VS prevents the
release of toxic factors involved in the loss of MN synaptic and
axonal dynamics.
Since we have observed an increase of miR-146a in the
WT MNs treated with the secretome from the mSOD1
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FIGURE 5 | sEVs derived from pre-miR-146a-treated mSOD1 astrocytes show enriched content in miR-146a, but not those from VS-treated cells. Astrocytes were
isolated from the cortex of SOD1-G93A (mSOD1) and wild type (WT) mice pups at 7-day-old and cultured for 13 days in vitro. Transfection with pre-miR-146a and
treatment with dipeptidyl vinyl sulfone (VS) were performed in mSOD1 astrocytes. Small extracellular vesicles (sEVs) were isolated from the secretome of astrocytes
by differential ultracentrifugation. (A) Results from one blot shows the expression of sEV markers (Alix and Flotillin-1). (B) Representative images obtained by
transmission electron microscopy of sEVs show their cup shape morphology. Results from (C) number of sEVs per cell, (D) concentration (sEVs number/mL), and
(E) size distribution derived from Nanoparticle Tracking Analysis using NanoSight. (F,G) RT-qPCR analysis of miRNA(miR)-146a expression in sEVs was performed.
Spike and SNORD were used as endogenous controls. Results are mean (±SEM) fold change vs. sEVs-derived WT astrocytes from at least three independent
experiments. *p < 0.05 vs. sEVs from WT astrocytes; ##p < 0.01 vs. sEVs from untreated mSOD1 astrocytes. One-way ANOVA followed by Bonferroni post hoc test
was used.
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FIGURE 6 | Both VS and pre-miR-146a treatment are effective in restoring the neuroprotective profile of mSOD1 astrocytes but reveal distinct benefits. Astrocytes
(Ast) were isolated from the cortex of SOD1-G93A (mSOD1) and wild type (WT) mice with 7-day-old and cultured for 13 days in vitro. Transfection with pre-miR-146a
or treatment with dipeptidyl vinyl sulfone (VS) was performed in mSOD1 astrocytes. Cell-derived secretome (sec) was incubated in WT NSC-34 motor neurons (MNs)
for 48 h. Analysis of (A) miRNA(miR)-146a, (B) fibroblast growth factor receptor 1 (FGFR1), (C) FGFR3, (F) synaptophysin, (G) post-synaptic protein 95 (PSD95), (H)
dynein, and (I) kinesin in WT MNs were assessed by RT-qPCR. SNORD110 was used as reference gene for (A) analysis and β-actin for (B,C,F–I) analysis. (D) Early
apoptotic cells (annexin V-PE positive and 7-AA negative) and (E) late apoptotic/necrotic cells (annexin V-PE and 7-AA positive) were assessed by Guava Nexin R©
Reagent in the WT MNs after secretome interaction. Results are mean (±SEM) fold change vs. MNs + secretome from WT astrocytes from at least three
independent experiments. ∗p < 0.05, ∗∗p < 0.01, and **** p < 0.0001 vs. MNs + secretome from WT astrocytes; #p < 0.05, ##p < 0.01, ###p < 0.001, and
####p < 0.0001 vs. MNs + secretome from mSOD1 astrocytes. One-way ANOVA followed by Bonferroni post hoc test was used.
astrocytes transfected with pre-miR-46a, we next performed
proteomic analysis to explore some of its potential targets in
these cells and better understand related effects. We found
one upregulated and 4 downregulated hits (Figure 7A and
Supplementary Table 5). The first was associated to the
induction of the pyruvate dehydrogenase complex encoded by
Dlat (Goguet-Rubio et al., 2016) that enhances the production
of ATP with benefits in preventing MN energetic stress that
characterizes ALS (Vandoorne et al., 2018). To that it may have
accounted the inhibition of the protein encoding for Atpif1
that also favors the ATP hydrolysis and ameliorates ALS MN
mitochondrial dysfunctionalities (Li et al., 2010; Chen et al.,
2014). These potential benefits may be increasingly sustained
by the downregulation of FtsJ RNA 2′-O-Methyltransferase 1
(Ftsj1), known to reduce apotosis (He et al., 2020). Another
important potential target was the inhibition of the Solute
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FIGURE 7 | Proteomic analysis reveals that treatment of mSOD1 astrocytes with pre-miR-146a reverts MN dysfunction and microglia activation by paracrine
mediators. Astrocytes were isolated from the cortex of SOD1-G93A (mSOD1) mice with 7-day-old and cultured for 13 days in vitro. Transfection with pre-miR-146a
was performed. Cell-derived secretome was added to (A) WT NSC-34 motor neurons (MNs) for 48 h or (B) naïve N9 microglia for 24 h. MA plots (left panels) were
obtained by comparison of the proteomic profiles of the treatment with the secretome of pre-miR-146a treated mSOD1 astrocytes and the untreated ones. Here, x
axis is the mean log2 intensity (fold change) of each protein between two profiles (A-value) and y axis is the average expression (signal_sum) of protein intensities
(M-value). Summary tables (right panels) show the obtained hits and their classification according to biological processes using PANTHER Classification System as
indicated in methods.
Carrier Family 2 (Facilitated Glucose Transporter) Member 13
protein encoded by Slc2a13, recently identified a risk factor in
frontotemporal dementia (Sirkis et al., 2019). Its silencing was
shown to diminish APP processing (Teranishi et al., 2015) and
may impact on the crosstalk between APP and mSOD1, which
seems to contribute to ALS pathology (Rabinovich-Toidman
et al., 2015). Also, adding to a better MN functionality is
the decrease of RNA-binding protein with multiple splicing
encoded by the Rbpms gene that favors synaptogenesis and
may be associated with the increased PSD-95 that we observed
(Hornberg et al., 2013).
These results clearly show distinct beneficial effects by
the secretome from VS-treated astrocytes with protective
properties on synaptic dynamics and axonal transport, while
those depending on pre-miR-146a treated astrocytes were
predominantly related with neuronal survival, miR-146a
enrichment and regulation of FGFR1 and FGFR3. As far as
we know, this is the first time that mSOD1 astrocytes are
described as showing an elevation of such fibroblast growth
factor receptors.
Secretome From mSOD1 Astrocytes
Transfected With Pre-miR-146a Shows to
Better Preserve Microglia Healthy State
Than the Treatment With VS
Besides affecting MNs, astrocytes also release soluble factors that
influence microglia activation, but such signaling events in the
context of ALS disease are still unclarified.
It is known that the expression of FGFR3 in microglia has
been linked to enhanced microglial migration and phagocytosis
of neuronal debris (Noda et al., 2014). However, inappropriate
phagocytosis of live neurons and excessive neuronal loss, termed
phagoptosis (Brown and Neher, 2014), may have detrimental
consequences on the patient outcome. Similarly, to our findings
on the effects produced by the secretome from mSOD1 astrocytes
on WT MNs, naïve N9 microglial cells showed increased gene
expression of FGFR3 (Figure 8B). Both VS and pre-miR-146a
immunomodulation of mSOD1 astrocytes were effective in
reducing such expression (p < 0.001). Further results showed
that the secretome of mSOD1 astrocytes induced early and late
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FIGURE 8 | Secretome from pre-miR-146a-treated mSOD1 astrocytes translates into microglial miR-146 increase and regulation of cell activation by the untreated
secretome, while also prevents cell demise similarly to VS modulation. Astrocytes (Ast) were isolated from the cortex of SOD1-G93A (mSOD1) and wild type (WT)
mice with 7-day-old and cultured for 13 days in vitro. Transfection with pre-miR-146a or treatment with dipeptidyl vinyl sulfone (VS) was performed in mSOD1
astrocytes. Secretome was isolated and incubated in naïve N9 microglia for 24 h. Expression of (A) miRNA(miR)-146a, (B) fibroblast growth factor receptor 3
(FGFR3), (E) inducible nitric oxide synthase (iNOS) and (F) tumor necrosis alpha (TNF-α) in microglia was assessed by RT-qPCR. SNORD110 was used as reference
gene for (A) analysis and β-actin for (B,E,F) analysis. (C) Early apoptotic (Annexin V-PE positive and 7-AAD negative), and (D) late apoptotic/necrotic cells (Annexin
V-PE and 7-AAD positive) were assessed by Guava Nexin R© Reagent in the microglia after secretome interaction. Results are mean (±SEM) fold change vs.
MG + secretome from WT astrocytes from at least three independent experiments. *p < 0.05 and **p < 0.01 vs. MG + secretome from WT astrocytes; ##p < 0.01,
###p < 0.001, and ####p < 0.0001 vs. MG + secretome from mSOD1 astrocytes. One-way ANOVA followed by Bonferroni post hoc test was used.
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apoptosis (Figures 8C,D, at least p < 0.05) that were prevented
when the cells were treated with pre-miR-146a or VS (only early
apoptosis). As expected, the secretome from mSOD1 astrocytes
also activated and polarized microglia to overexpress iNOS
(Figure 8E, p < 0.01) and TNF-α mRNAs (Figure 8F, p < 0.01).
Only the treatment of mSOD1 astrocytes with pre-miR-146a
showed to be efficient in counteracting the expression of such
inflammatory mediators and in switching microglia into their
steady-state (p < 0.01).
As before, and since we found an overexpressed miR-146a
in the microglia treated with the secretome from pre-miR-
146a mSOD1 astrocytes, we proceeded to proteomic analysis to
investigate how the potential targets related with the improved
effects we observed. Downregulation of the cyclin-dependent
kinase 1 levels (encoded by Cdk1) may have contributed to the
regulation of iNOS and TNF-α in the microglia treated with the
secretome from mSOD1 astrocytes relatively to the untreated
one (Figure 7B and Supplementary Table 6). Actually, increase
of iNOS and TNF-α is associated to microglia activation and
neuroinflammation (Sheng et al., 2011) and CDK inhibitors
were shown to reduce them in several conditions (Leitch
et al., 2009; Skovira et al., 2016). As for the decrease in the
metalloproteinase with thrombospondin motifs 1, encoded by
the gene Adamts1, it was suggested to be a modulator of the
immune cell response in tumors (Rodriguez-Baena et al., 2018),
and found elevated in LPS-activated microglia (Chiu et al., 2013).
In what concerns the immunoglobulin superfamily DCC subclass
member 4, encoded by Igdcc4 and accepted as a biomarker of
hepatocellular carcinoma (Zweerink et al., 2020) and of innate
immune/inflammatory response (Sanz-Pamplona et al., 2014),
it should be explored in the future as part of the recovering
microglia steady-state profile by pre-miR-146a in ALS cortical
astrocytes through paracrine signaling.
In sum, both pre-miR-146a and VS modulatory effects
on ALS astrocytes prevented secretome-mediated microglial
demise and FGFR3 increase. However, the transfection of the
mSOD1 astrocytes with pre-miR-146a had a higher efficiency in
preventing the microglial elevation of iNOS and TNF-α gene
expression levels than the VS treatment. We next investigated
if the effects observed on the microglia deactivation by the
secretome from the mSOD1 astrocytes treated with pre-miR-
146a were mediated by sEVs, previously shown to be enriched
in this miRNA in the section “Overexpression of Pre-miR-146a
in mSOD1 Astrocytes Is Recapitulated in Their Derived sEVs.”
sEVs From mSOD1 Astrocytes Treated
With Pre-miR-146a Are Preferentially
Captured by Microglia, Enhancing Its
Intracellular Upregulation, and Together
With VS Counteract Cell Activation by
the Pathological sEVs
Misfolded and mutated SOD1 were shown to be propagated
intercellularly by sEV-dependent and independent mechanisms
(Grad et al., 2014), and to have impact on astrocyte protein
secretion pathways, thus accounting to MN pathology
and dissemination (Basso et al., 2013). We have previously
demonstrated that sEVs from NSC-34 hSOD1G93A MN-like
cells cause alterations on N9 microglia polarization (Pinto
et al., 2017). However, the effects produced by the secretome
of pathological astrocytes on microglia polarization have been
scarcely investigated.
Similarly to what we have previously observed for WT MNs,
the secretome from pre-miR-146a-treated mSOD1 astrocytes
increased the expression of this miRNA on naïve N9 microglial
cells (Figure 8A). However, while MNs are not able to collect
entire sEVs, microglia easily engulf them, as we showed (Pinto
et al., 2017). Therefore, we isolated sEVs from the secretome of
mSOD1 astrocytes untreated or treated with either pre-miR-146a
or VS, and we investigated the presence of labeled sEVs in the N9
microglial cells 24 h after incubation. As shown in Figures 9A,B
no differences in the number of sEVs incorporated by microglia
were obtained when isolated from mSOD1 astrocyte secretome
relatively to the WT astrocyte one. However, sEVs were found
more densely internalized by microglia (p < 0.01) in the case of
the pre-miR-146a strategy, than by VS. This feature may have
accounted for the miR-146a elevation in the cells (p < 0.001,
Figure 9C), due to sEV enriched cargo in miR-146a (Figure 5F).
Interestingly, both pre-miR-146a and VS treatment in
mutated astrocytes produced sEVs able to prevent iNOS
(p < 0.01, Figure 9D) and TNF-α (at least p < 0.001,
Figure 9E) upregulation relatively to sEVs from untreated
mSOD1 astrocytes. This is a very interesting result, if we consider
that VS-derived secretome was unable to prevent microglia
activation, while its isolated sEVs showed such property.
Data highlight the differential roles of the secretome
(ineffective) and of the isolated sEVs (effective) from the VS-
treated astrocytes in recovering microglia steady-state, while
indicate to be independent of miR-146a content. However, in the
case of astrocytes treated with pre-miR-146a, both the secretome
and their isolated sEVs, suppressed microglia activation by
a mechanism that is suggestive to depend on the paracrine
influence of miR-146a expression.
DISCUSSION
Currently, there are no effective therapies for ALS and the
recent advances in this field converges in the modulation of
the inflammatory and toxic environment by controlling glial
activation (Liu and Wang, 2017). Indeed, increased evidences
have shown that reactive astrocytes impair the survival of MNs
(Díaz-Amarilla et al., 2011; Meyer et al., 2014; Qian et al., 2017;
Gomes et al., 2019).
We have recently identified the presence of a deregulated set
of reactive markers in mSOD1 cortical astrocytes isolated from 7-
day-old mSOD1 mice cultured for 13 DIV, which were similarly
present in the symptomatic stage of the same animals (Gomes
et al., 2019). The ALS-disease characteristic phenotype included
a low GFAP expression, but increased levels of S100B, Cx43,
vimentin and HMGB1. By showing the same markers identified
in the symptomatic stage of the mSOD1 mice their characteristic
fingerprint with low GFAP levels seems to be disease specific.
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FIGURE 9 | Microglia treated with sEVs from mSOD1 astrocytes modulated with pre-miR-146a or VS show different sEV internalization and miR-146a expression,
but similar protection from activation by untreated-sEVs. Astrocytes were isolated from the cortex of SOD1-G93A (mSOD1) and wild type (WT) mice with 7-day-old
and cultured for 13 days in vitro. Transfection with pre-miR-146a or VS treatment was performed in mSOD1 astrocytes. Small extracellular vesicles (sEVs) were
isolated by differential ultracentrifugation and labeled with PKH67 cell linker, followed by incubation with naïve N9 microglia for 24 h. (A) Representative images of
sEVs stained with PKH67 cell linker (green); (B) mean fluorescence area positive for PKH67-sEVs per cell. Cell nuclei were stained with Hoechst dye (blue).
Expression of (C) miRNA(miR)-146a, (D) inducible nitric oxide synthase (iNOS) and (E) tumor necrosis alpha (TNF-α) in microglia was assessed by RT-qPCR.
SNORD110 was used as reference gene for (C) analysis and β-actin for (D–E) analysis. Results are mean (±SEM) fold change vs. MG + sEVs from WT astrocytes
from at least three independent experiments. ***p < 0.001 and ****p < 0.0001 vs. MG + sEVs from WT astrocytes; ##p < 0.01, ###p < 0.001, and ####p < 0.0001
vs. MG + sEVs from mSOD1 astrocytes. One-way ANOVA followed by Bonferroni post hoc test was used. Scale bar represents 20 µm.
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FIGURE 10 | Schematic representation of the efficacy of miR-146a replenishing methods to recover the neuroprotective phenotype of aberrant mSOD1 cortical
astrocytes, and in preventing toxic paracrine signaling toward motor neurons and microglia by the mediators released from the pathological astrocytes. Astrocytes
were isolated from the cortex of SOD1-G93A (mSOD1) mice pups at 7-day-old and cultured for 13 days in vitro, showing an aberrant/reactive phenotype. Treatment
with glycoursodeoxycholic acid (GUDCA) and dipeptidyl vinyl sulfone (VS) abrogated reactive markers, with additional re-establishment of glial fibrillary acidic protein
(GFAP) and miR-146a by VS, evidencing their reparative ability. Transfection of mSOD1 astrocytes with pre-miR-146a also attenuated their phenotypic aberrancies
and intracellular Ca2+ ([Ca2+]i) overload. Moreover, such treatment increased miR146a content in the cell-derived small extracellular vesicles (sEVs), and mediated
miR-146a enrichment in SOD1-WT motor neurons (MNs) and naïve N9 microglial cell. Secretome from mSOD1 astrocytes increased early/late apoptosis and
fibroblast growth factor receptor (FGFR) gene levels in MNs and microglia, effects that were prevented by pre-miR-146a or VS modulation. These strategies led to a
secretome with preventable properties over the deregulation of synaptic dynamics and axonal transport upon the pathological extracellular milieu from mSOD1
astrocytes. The pre-miR-146a-treated cells also prevented microglia activation through their secretome or isolated sEVs, but in the case of VS only the isolated sEVs
showed such property. Data reveal that both pre-miR-146a and VS-mediated miR-146a replenishment in mSOD1 cortical astrocytes are promising approaches to
recover the neuroprotective phenotype of ALS cortical astrocytes and the microglia and MN homeostatic balance in the disease. [Ca2+]i, intracellular calcium; GFAP,
glial fibrillary acidic protein; FGFR, fibroblast growth factor receptor; GUDCA, glycoursodeoxycholic acid; iNOS, inducible nitric oxide synthase; miR-146a,
miRNA-146a; SOD1, superoxide dismutase 1; TNF-α, tumor necrosis alpha; VS, dipeptidyl vinyl sulfone.
This profile is in agreement with the previous one found in
the SC of adult symptomatic mSOD1 rats (Díaz-Amarilla et al.,
2011). Astrocyte reactivity is usually associated to elevated levels
of GFAP (Eng and Ghirnikar, 1994). Indeed, GFAP was found
elevated in the cerebrospinal fluid and in the SC of patients
with ALS (Fujita et al., 1998; Benninger et al., 2016), as well as
in isolated adult astrocytes using supplementation with growth
factors from the mSOD1 mice (Tripathi et al., 2017). However,
our data and that of others (Rossi et al., 2008; Díaz-Amarilla et al.,
2011; Cunha et al., 2018; Gomes et al., 2020) are consistent with
a downregulation of GFAP in the presence of reactive markers
that also include increased Ki-67, together contributing to
denominate astrocytes in ALS as having an aberrant phenotype.
In a recent consensus statement, it is referred that the increase in
GFAP expression do not correlate with increased injury, reactive
response to pathological stimuli or altered functions of reactive
astrocytes (Escartin et al., 2021). In conformity, it should be
used instead a combination of molecular markers to qualify
astrocytes as reactive and as having a disease-specific signature.
In this context, cortical homogenates from the symptomatic
mSOD1 mice and isolated astrocytes from such animal pups
showed increased reactive astrocyte markers, decreased GLT-1
and GFAP levels, and the pioneering downregulated expression
of miR-146a (Gomes et al., 2019, 2020). Such reduction was
even present in the presymptomatic stage and could not be
found in astrocytes from the spinal cord (Cunha et al., 2018),
suggesting regional astrocyte heterogeneity and their different
contribution to bulbar and spinal forms of ALS disease. Such
findings indicate that different therapeutic approaches may be
required, depending on the local of disease onset, and that
replenishment of miR-146a in cortical astrocytes may reveal a
promising strategy.
Interestingly, miR-146a-enriched stem cell secretome was
recently suggested to have proangiogenic and anti-inflammatory
properties (Waters et al., 2019). For that reason and given the
importance of miR-146a in controlling astrocyte inflammation
(Iyer et al., 2012), we decided to test the efficacy of pre-miR-
146a and immunomodulatory compounds, such as GUDCA
and VS (Falcão et al., 2017; Vaz et al., 2019) in reverting
astrocyte reactivity and miR-146a replenishment. Our results
demonstrated that VS induced upregulation of miR-146a and
downregulation of its targets, while GUDCA did not change such
levels. This is in line with our previous studies that demonstrated
the ability of VS in modulating miR-146a expression (Falcão
et al., 2017; Vaz et al., 2019). Furthermore, GUDCA reduced the
expression of vimentin and Cx43, exerting a modulatory role
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on astrocyte reactivity, in accordance with our previous data
(Fernandes et al., 2007). However, VS showed more broader
effects, not only by restoring the levels of GFAP and decreasing
vimentin and Cx43 expression, but also by downregulating
S100B and HMGB1 levels, corroborating its anti-inflammatory
properties previously observed in microglial models of ALS (Vaz
et al., 2019) and Alzheimer’s disease (Falcão et al., 2017). To note
that neither GUDCA nor VS showed to compromise cell viability.
Then, we hypothesized if the attenuation of such aberrancy
by these compounds might be related with the modulation of
miR-146a expression.
To verify such supposition, we restored the normal levels
of miR-146a by transfecting mSOD1 astrocytes with pre-miR-
146a. Re-establishment of GFAP, vimentin, Cx43, HMGB1
and S100B toward control WT levels revealed its therapeutic
potential. Actually, vimentin is not only an intermediate filament
protein involved in cellular processes, such as cell adhesion,
migration and proliferation, promoting wound healing (Ivaska
et al., 2007), but it is also a known marker of immature
astrocytes, associated with a reactive gliosis and leading to
thicker bundles in the astrocytic processes (Cheng and Eriksson,
2017). Usually, the expression of GFAP replaces vimentin in
differentiated astrocytes (Roybon et al., 2013). In the case
of the cortical ALS astrocytes data suggest that they sustain
an immature-like reactive phenotype. The correction of the
low levels of miR-146a seems to contribute to abolish such
ALS-disease phenotype of cortical astrocytes. Regulation of
vimentin and GFAP levels by pre-miR-146a are in accordance
with a study wherein miR-146a overexpression increased
GFAP expression and attenuated proliferation, migration and
tumorigenic potential of glioma cells (Mei et al., 2011; Xiao et al.,
2015). We also found decreased S100B and HMGB1 expression
gene levels in pre-miR-146a-treated mSOD1 astrocytes. This
is in line with a previous study that suggested the increased
astrocytic S100B expression as an early occurring event in ALS
and a contributor for neurodegeneration (Serrano et al., 2017).
These Authors observed that its inhibition in mSOD1 astrocytes
decreased the expression of proinflammatory/reactive genes.
Besides, this attenuation of astrocyte-inflammatory potential
supports the role of miR-146a as a negative regulator of the
NF-κB inflammatory pathway in astrocytes (Taganov et al.,
2006; Iyer et al., 2012). Concerning Cx43, it is known
to modulate proliferation, migration and differentiation of
astrocytes (Homkajorn et al., 2010). Its upregulation was detected
in mSOD1 astrocytes, corroborating previous studies in rodent
models (Díaz-Amarilla et al., 2011; Cui et al., 2014), and
the restoration of Cx43 normal levels in pre-miR-146a-treated
mSOD1 astrocytes may associate to its ability to regulate
inflammatory response and attenuate gliosis (Mei et al., 2011).
Like GUDCA and VS, pre-miR-146a transfection also did not
activate early/late apoptosis.
Proteomic analysis showed that pre-miR-146a induced an
upregulation of the NCF1 protein that we hypothesize to
be an attempt to control the reactive/immune response in
mSOD1 astrocytes, as demonstrated in chronic inflammatory
disorders (Holmdahl et al., 2016; Zhao et al., 2017). ZBTB10
was found elevated during gliogenesis and linked to ZBTB20
for differentiation and maturation of neocortical astrocytes
(Nagao et al., 2016; Araújo, 2019). Moreover, ZBTB10 was
also suggested to be associated to DNA damage repair at
telomeres (Bluhm et al., 2019). As for HMGN2, it belongs to a
family of proteins associated to astrocyte differentiation during
development (Nagao et al., 2014). Both ZBTB20 and HMGN2
may be relevant protein targets to be used toward the recovery
of the neuroprotective phenotype by the ALS cortical astrocytes
which, in our view, deserve to be explored. The observed
upregulation of ALS2CL, by regulating the alsin-mediated
endosome, might induces sEV formation (Hessvik and Llorente,
2018) and the activation of the autophagy-endolysosomal system
(Otomo et al., 2012). Together with the PZP upregulation
associated to a sustained extracellular proteostasis and inhibition
of misfolded protein accumulation (Cater et al., 2019), they
might act together to promote mSOD1 clearance from astrocytes
by sEVs and autophagy. Indeed, PZP elevation was found
in senile plaques and in glial cells in Alzheimer’s disease,
possibly having a protective role (Ijsselstijn et al., 2011;
Nijholt et al., 2015).
To assess whether reversal of mSOD1 astrocyte aberrancies
by VS was mediated via miR-146a regulation, we depleted its
expression in WT astrocytes with a miR-146a inhibitor, before
using VS. Anti-miR-146a-transfected WT astrocytes acquired
the aberrant phenotype that characterize ALS cortical astrocytes.
Interestingly, VS was not only able to restore miR-146a levels
in such condition, but also to revert GFAP, S100B and vimentin
toward steady-state levels. In sum, our results indicate that
targeting downregulated miR-146a, either with pre-miR-146a
or VS, constitutes a good strategy to counteract the atypical
reactivity of ALS cortical astrocytes associated to the miR-
146a depletion.
Given the established contribution of ALS astrocytes on
MN death and the possible involvement of astrocytic Ca2+
dysregulation in this process (Kawamata et al., 2014), we
investigated its presence and if it was modulated by either pre-
miR-146a or VS treatments. Our results revealed a baseline
increase of intracellular Ca2+ in mSOD1 astrocytes that was
prevented by VS co-incubation, together with elevated frequency
of Ca2+ transients after glutamate stimulation, what may impact
on synapse integrity (Guerra-Gomes et al., 2017). Astrocytes
possess glutamate-sensitive ion channels and can respond to
glutamate with a fast and oscillatory elevation of cytoplasmic free
Ca2+ by autocrine and paracrine effects (Cornell-Bell et al., 1990).
We hypothesize that the excess of Ca2+ in mSOD1 astrocytes
may derive from ER stores, as observed in the SC of mSOD1
mice (Kawamata et al., 2014), or be caused by the aberrant
Cx43 overexpression (Almad et al., 2016), inducing alterations
in neuronal excitability, synaptic transmission and plasticity (Lu
et al., 2010). As so, pre-miR-146a was able to reduce the number
of [Ca+]i transients in mSOD1 astrocytes and to downregulate
Cx43 expression. Previous studies observed the reduction in
Ca2+ responses in the presence of a Cx43 blocker in ALS
astrocytes (Almad et al., 2016, 2020).
Astrocytes are highly secretory cells, with their secretome
containing hundreds of molecules. In ALS, it is accepted that
astrocytes have a paracrine contribution to neurodegeneration
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and microglial activation, but the mechanisms associated are
poorly explored (Pehar et al., 2017). As a component of
secretome, sEVs mediate the interaction between neurons and
glial cells and are responsible for the delivery of proteins, lipids,
mRNAs and miRNAs in the recipient cell, being considered
potential vehicles for drug delivery (Basso and Bonetto, 2016).
Our observation that mSOD1 astrocytes release sEVs with low
miR-146a content is in line with our previous findings (Gomes
et al., 2020). In the same study, we established that mSOD1
astrocytes contribute to the neuronal degeneration when these
cells are co-cultured with ALS MNs. Indeed, mSOD1 astrocytes
selectively provoke toxicity to MNs (Di Giorgio et al., 2007; Nagai
et al., 2007; Díaz-Amarilla et al., 2011; Haidet-Phillips et al., 2011;
Gomes et al., 2019) and their secretome was found to play an
important role (Nagai et al., 2007).
We observed that early and late apoptosis were induced by
the secretome from the pathological ALS astrocytes, leading
to a reduced expression of synaptophysin, PSD-95, dynein,
and kinesin in MNs, thus compromising synaptic and axonal
dynamics. Synaptophysin, a presynaptic membrane protein, was
found reduced in MNs from mSOD1 mice and shown to
contribute to motor deficits (Zang et al., 2005). The postsynaptic
PSD-95, also important for synaptic plasticity (Zhang and
Lisman, 2012), has been found reduced in neurodegenerative
diseases, including ALS (Fogarty, 2019). Contribution of ALS
astrocytes to synaptic failure is an established feature (Casas et al.,
2016). In particular, these cortical mSOD1 astrocytes showed to
reduce neurite length and synaptophysin expression in coculture
with NSC-34 hSOD1 WT MN-like cells (Gomes et al., 2019).
Defects in the anterograde and retrograde transports by kinesin
and dynein, respectively, also occur in ALS neurodegeneration
in patients and in mSOD1 mice (De Vos and Hafezparast,
2017). Inefficient anterograde transport was shown to reduce
the transport of synaptic vesicle precursors, contributing to the
decrease in synaptic vesicle density (Yonekawa et al., 1998) that
is reflected by the reduced expression of the synaptic proteins,
as we observed. Secretome from pre-miR-146a-treated mSOD1
astrocytes, but not from VS-treated ones, restored PSD-95 and
kinesin levels found deregulated by the pathological paracrine
signaling over WT MNs.
We identified for the first time that FGFR1 and FGFR3
gene expression levels, receptors of fibroblast growth factor-2
(FGF2), increased in MNs upon the secretome from mSOD1
astrocytes. FGF2 is highly produced in reactive astrocytes after
injury and ischemia (Reilly and Kumari, 1996; Clarke et al., 2001)
and their elevation was noticed in the CSF from ALS patients
(Johansson et al., 2003; Ekestern, 2004). The upregulation of
FGFR1 and FGFR3 identified in our study by the secretome from
mSOD1 astrocytes may contribute to axonal damage involving
the ERK/MAPK signaling (Huang et al., 2020). Instead, the
secretome derived from pre-miR-146a-treated mSOD1 astrocyte
was unique in decreasing the expression of these receptors and
together with VS prevented the induced MN apoptosis upon
treatment with the pathological astrocyte-derived secretome.
Motor neuron proteomic analysis revealed that pre-miR-146a
increases the E2 component of the pyruvate dehydrogenase
complex encoded by the Dlat gene (Goguet-Rubio et al.,
2016), leading to the production of ATP that is required to
continuously provide energy to maintain normal MN function
with a high relevance in ALS (Vandoorne et al., 2018). By
downregulating ATP1F1, pre-miR-146a may also ameliorate
mitochondrial respiratory chain dysfunction because it inhibits
ATPase activity (Chen et al., 2014), contributing to sustain
ALS MN mitochondrial functionality (Li et al., 2010; Chen
et al., 2014), and thus preventing the apoptosis induced by
the secretome from pre-miR-146a-treated mSOD1 astrocytes. In
conformity, the decreased expression of FTSJ1, as we found,
was also associated to the inhibition of apoptosis in cancer
(He et al., 2020). It was interesting to observe a reduction of
SLCA13, since this transporter was identified as a risk factor
for frontotemporal dementia (Sirkis et al., 2019). By being
reduced, it prevents APP processing (Teranishi et al., 2015) and
the interaction between SOD1 and APP, which are known to
lead to synaptic dysfunctions and associated neuroinflammation
and neurodegeneration events in ALS (Rabinovich-Toidman
et al., 2015). We also found downregulation of RBPMS
in MNs following the interaction with the secretome from
pre-miR-146a-treated mSOD1 astrocytes. Its transcript was
found downregulated in the axonal transcriptome from MNs
overexpressing human mSOD1 (Nijssen et al., 2018) and showed
to inversely affect synapse density (Hornberg et al., 2013).
VS treatment exceeded the beneficial effects of pre-miR-146a
treatment by promoting MN functionality through upregulation
of synaptophysin, PSD-95, dynein and kinesin transcripts and
by avoiding early cell death by apoptosis. This is in line with
a previous study describing vinyl sulfones as neuroprotective
agents in the treatment of Parkinson’s disease (Woo et al., 2014;
Choi et al., 2019). Increased levels of miR-146a in MNs were
observed after treatment with the secretome from the pre-miR-
146a-treated mSOD1 astrocytes, but not with that from VS
treatment. We may hypothesize that the enriched content of
the secretome or their isolated sEVs in miR-146a may have
accounted for such MN upregulation and eventually the observed
benefits. Indeed, previous studies demonstrated that miR-146a is
important for neuronal survival and differentiation (Qu et al.,
2019; Fregeac et al., 2020), as well as for axonal growth (Jia
et al., 2016). This is not the case of VS, suggesting that its
paracrine neuroprotective effect is not exclusively dependent on
sEV-derived miR-146a. In contrast, their effectiveness might be
related with soluble miR-146a or other neuroprotective factors,
an interesting hypothesis to be explored in future studies.
The secretome from mSOD1 astrocytes also switched
microglia to a pro-inflammatory subtype by increasing iNOS
and TNF-α mRNA expression, in accordance with studies
where mSOD1 astrocytes led to the activation of microglia,
thus contributing to disease progression (Yamanaka et al.,
2008). Moreover, we observed the activation of early/late
apoptosis and an increase of FGFR3 expression. Injury was
shown to upregulate the FGFR3 expression in both astrocytes
and microglia and FGF2 appears to have a dual role, by
firstly inducing gliosis and secondly neuroprotection (Goddard
et al., 2002). Here, we may speculate that, as observed for
damaged neurons, cortical ALS astrocytes release FGF2 and
enhances the expression of FGFR3, which has been associated
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to neuroprotection against glutamate toxicity and increased
microglial migration and phagocytosis (Noda et al., 2014).
Nevertheless, excessive neuronal phagoptosis also contributes
to a range of neurodegenerative diseases, including ALS
(Brown and Neher, 2014). Therefore, if we consider that the
secretome derived from both pre-miR-146a and VS-treated
astrocytes reduces FGFR3 levels in microglia, it may then
prevent reactivity and excessive phagoptosis. However, only the
secretome derived from pre-miR-146a -treated astrocytes averted
microglial inflammatory activation.
To better understand the effects produced by the secretome
from mSOD1 astrocytes treated with pre-miR-146a on microglia
we performed proteomic analysis. Among the effects produced
we noticed a reduction in Cdk1 that may have contributed to the
decrease of iNOS and TNF-α transcripts by the modulated
secretome. Such proinflammatory signaling activation,
characteristic of a polarized activated microglia (Sheng et al.,
2011), was shown to be prevented by CDK inhibitors (Leitch
et al., 2009; Skovira et al., 2016). Similarly contributing to
counteract the activation of microglia is the reduction we
found on Adamts1, once its upregulation was identified in
LPS-activated microglia (Chiu et al., 2013) and associated to a
tumor inflammatory response (Rodriguez-Baena et al., 2018).
These findings indicate that pre-miR-146a contributes to a less
polarized microglia phenotype. Regarding Igdcc4, also described
as being involved in immune response (Sanz-Pamplona et al.,
2014) and a biomarker in hepatocellular carcinoma (Zweerink
et al., 2020), further studies should investigate its precise
role in microglia.
Now going for the interaction of sEVs on microglia, though
we did not observe changes in the concentration and size of
sEVs derived from pre-miR-146a-treated astrocytes, an increased
internalization of sEVs in microglia was noticed, when compared
with sEVs derived from the pathological untreated mSOD1
astrocytes or VS-treated ones. This increased uptake by the
microglial cells is not surprising since it was demonstrated that
miR-146a leads to the upregulation of several microglia surface
receptors (Saba et al., 2012) that most likely enable the uptake of
sEVs. Also, previous studies demonstrated that microglia are one
of the neural cells that show higher ability for sEV incorporation
(Fitzner et al., 2011; Pinto et al., 2017; Xia et al., 2019).
In a previous study we evidenced that sEVs derived
from the secretome of mSOD1 MNs with an enriched cargo
in miR-124 were able to activate microglia (Pinto et al.,
2017). Similarly, our sEVs depleted in miR-146a and isolated
from the secretome of mSOD1 cortical astrocytes led to
increased gene expression of iNOS and TNF-α. We further
demonstrated that such effect was counteracted when we
used pre-miR-146a or VS-treatment in mSOD1 cortical
astrocytes. This is in line with studies evidencing that EVs
containing miR-146a attenuate inflammation, supporting
tissue repair and regeneration (Alexander et al., 2015;
Waters et al., 2019; Wu et al., 2019). Moreover, miR-146a
packaged into EVs and transferred into macrophages showed
therapeutic efficacy against sepsis (Song et al., 2017), thus
reinforcing its protective effects. Interestingly, despite not
having increased cargo in miR-146a, sEVs isolated from the
secretome of VS-treated mSOD1 astrocytes also demonstrated
ability to switch the activated microglia into the steady-
state phenotype, indicating that miR-146a is not the sole
neuroprotective factor involved in the reestablishment of the
healthy microglia state.
In sum, our study highlights that the downregulation of
miR-146a in mSOD1 cortical astrocytes is responsible, at
least in part, by the reactivity and aberrant features of these
glial cells. We propose pre-miR-146a transfection and VS
treatment as efficient strategies to induce miR-146a upregulation
in cortical ALS astrocytes toward cell revival through the
abrogation of their reactive/aberrant phenotype. These potential
therapeutic approaches have additional advantages in re-
establishing microglia and MN homeostatic states by paracrine
signaling. Comparative effects of the miR-146a replenishing
methods, i.e., pre-miR-146a, GUDCA and VS, in the ability to
recovery of the neuroprotective phenotype of cortical astrocytes
from mSOD1 mice, and the resulting paracrine signaling on
WT MNs and N9 microglial cells are schematically represented
in Figure 10. Overall, we consider sEV-enrichment in VS and
pre-miR-146a cargoes as opportunities for neuro-glial restorative
therapy in ALS disease.
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